The Utility of Cystathionine Assessment using proton MR Spectroscopy for the Preoperative Differential Diagnosis of Adult-Type Diffuse Gliomas
American Journal of Neuroradiology · 2026
DOI: 10.3174/ajnr.a9192 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Neuroradiology, 2026. Verfasst von Kazufumi Kikuchi und 10 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Clinical Radiology (K.K., D.M., M.K., K.I.), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan kikuchi.ka…. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma, Cystathionine, Proton Magnetic Resonance Spectroscopy. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND AND PURPOSE: Adult-type diffuse gliomas-astrocytoma, isocitrate dehydrogenase (IDH)-mutant; oligodendroglioma, IDH-mutant and 1p/19q-codeleted; and glioblastoma, IDH-wild-type-have distinct prognoses and treatment responses. Accurate preoperative subtype estimation is, therefore, important for clinical decision-making. Proton MR spectroscopy (1H-MRS) enables noninvasive assessment of tumor metabolism. Cystathionine, detectable at 2.72 ppm, has been proposed as a metabolic marker of oligodendroglioma, but its diagnostic performance across adult-type diffuse gliomas remains incompletely defined. This study evaluated the utility of cystathionine quantification by 1H-MRS for differentiating glioma subtypes and assessed whether combined analysis with 2-hydroxyglutarate (2HG) improves diagnostic performance. MATERIALS AND METHODS: Eighty-five patients with histologically and molecularly confirmed adult-type diffuse gliomas (25 oligodendrogliomas, 28 astrocytomas, 32 glioblastomas) underwent preoperative 3T MRI including the single-voxel point-resolved spectroscopy sequence for 1H-MRS (TE = 97 ms). Spectra with severe artifacts were excluded; no cases were excluded on the basis of full width at half maximum (FWHM < 12.8 Hz, 0.1 ppm at 3T). Metabolites were quantified using LCModel, with concentrations normalized to the unsuppressed water signal and relaxation-corrected. Group comparisons of cystathionine levels were performed using Kruskal-Wallis and Bonferroni-corrected pair-wise tests. The receiver operating characteristic analysis evaluated diagnostic performance for differentiating oligodendrogliomas from astrocytomas and glioblastomas. Supplementary analyses excluding spectra with cystathionine Cramér-Rao lower bounds (CRLB) ≥ 50% and combined cystathionine-2HG receiver operating characteristic were also performed. RESULTS: Cystathionine levels were highest in oligodendrogliomas (mean, 1.040 [SD, 0.908] mM), intermediate in glioblastomas, and lowest in astrocytomas (mean, 0.437 [SD, 0.403] mM). Oligodendrogliomas showed significantly higher levels than astrocytomas (P = .003), whereas no significant difference was observed between oligodendrogliomas and glioblastomas. Receiver operating characteristic analysis showed moderate diagnostic performance (area under the curve [AUC] = 0.69 for oligodendroglioma vs astrocytoma; AUC = 0.56 for oligodendroglioma vs glioblastoma). After CRLB-based exclusion, sensitivity increased but specificity decreased (AUC = 0.83 for oligodendroglioma vs astrocytoma). Combining cystathionine with 2HG modestly improved AUCs (0.72 and 0.61, respectively). CONCLUSIONS: Cystathionine quantification by 1H-MRS reflects biologically meaningful metabolic differences among adult-type diffuse gliomas, with higher levels characteristic of oligodendrogliomas compared with astrocytomas. However, overlap with glioblastomas limits its role as a stand-alone discriminator. When interpreted alongside 2HG and conventional imaging features, cystathionine may serve as a supportive metabolic marker to enhance preoperative glioma subtype classification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Clinical Radiology (K.K., D.M., M.K., K.I.), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan kikuchi.kazufumi.953@m.kyushu-u.ac.jp.
- Department of Molecular Imaging and Diagnosis (K.Yamashita), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- From the Department of Clinical Radiology (K.K., D.M., M.K., K.I.), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Neurosurgery (D.K., R.H., Y.F., R.O., K.Yoshimoto), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Radiology (O.T.), Faculty of Medicine, Saga University, Saga City, Saga, Japan.
ORCID-Profile: Koji Yamashita, Yutaka Fujioka, Kousei Ishigami
Zitieren
APA
Kikuchi, K., Yamashita, K., Momosaka, D., Kusunoki, M., Kuga, D., Hatae, R., Fujioka, Y., Otsuji, R., Togao, O., Yoshimoto, K., & Ishigami, K. (2026). The Utility of Cystathionine Assessment using proton MR Spectroscopy for the Preoperative Differential Diagnosis of Adult-Type Diffuse Gliomas. American Journal of Neuroradiology. https://doi.org/10.3174/ajnr.a9192
Vancouver
Kikuchi K, Yamashita K, Momosaka D, Kusunoki M, Kuga D, Hatae R, et al. The Utility of Cystathionine Assessment using proton MR Spectroscopy for the Preoperative Differential Diagnosis of Adult-Type Diffuse Gliomas. American Journal of Neuroradiology. 2026. doi:10.3174/ajnr.a9192
BibTeX
@article{Kikuchi2026,
author = {Kikuchi, Kazufumi and Yamashita, Koji and Momosaka, Daichi and Kusunoki, Masaoki and Kuga, Daisuke and Hatae, Ryusuke and Fujioka, Yutaka and Otsuji, Ryosuke and Togao, Osamu and Yoshimoto, Koji and Ishigami, Kousei},
title = {The Utility of Cystathionine Assessment using proton MR Spectroscopy for the Preoperative Differential Diagnosis of Adult-Type Diffuse Gliomas},
journal = {American Journal of Neuroradiology},
year = {2026},
doi = {10.3174/ajnr.a9192}
}
EUVIMED